Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
JERSEY CITY, N.J. , May 24, 2018 /PRNewswire/ --  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at American Society for Microbiology (ASM) Microbe 2018,
View HTML
Toggle Summary SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention
JERSEY CITY, N.J. , May 23, 2018 /PRNewswire/ --  SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti , M.D., President and Chief Executive Officer of SCYNEXIS , will
View HTML
Toggle Summary SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
Enrollment complete in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018 Phase 3 registration program in VVC planned for the fourth quarter of 2018 IV SCY-078 program continues to advance; Phase 1 study with liposomal formulation expected to initiate in the third quarter of 2018
View HTML
Toggle Summary SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
QIDP provides five additional years of market exclusivity, and Fast Track expedites the regulatory path Enrollment completed in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018 Initiation of Phase 3 registration program in VVC planned for the fourth quarter of 2018, with
View HTML
Toggle Summary SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
Published study further demonstrates in vitro activity of SCY-078 against Aspergillus strains when used alone or in combination Clinical efficacy against Aspergillus strains to be tested in Phase 2 trial to begin in third quarter of 2018 Antifungal activity against Pneumocystis supports potential
View HTML
Toggle Summary SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
JERSEY CITY, N.J. , April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at the 28 th European Congress of
View HTML
Toggle Summary SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference
JERSEY CITY, N.J. , March 21, 2018 /PRNewswire/ --  SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 17 th Annual Needham Healthcare
View HTML
Toggle Summary SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
Pre-clinical data demonstrates inhibitory activity of SCY-078 against C. auris Two ongoing trials - FURI and CARES - to study oral SCY-078 in patients with refractory fungal infections, including C. auris JERSEY CITY, N.J. , March 20, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
Robust enrollment continues in Phase 2b VVC trial with top-line data expected in mid-2018 IV SCY-078 program advancing, with liposomal IV formulation to be tested in a Phase 1 study in the third quarter of 2018 Completion of recent $30.0 million equity offering strengthens Company's cash position
View HTML
Toggle Summary SCYNEXIS to Present at the 30th Annual ROTH Conference
JERSEY CITY, N.J. , March 7, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 30 th Annual ROTH Conference at
View HTML